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Cryptococcal meningitis (CM) is one of the leading oppor-
tunistic infections associated with human immunodeficiency 
virus (HIV) infection (1). The worldwide burden of CM 
among persons living with HIV/acquired immunodeficiency 
syndrome (AIDS) was estimated in 2009 to be 957,900 cases, 
with approximately 624,700 deaths annually (1). The high 
burden of CM globally comes despite the fact that crypto-
coccal antigen (CrAg) is detectable weeks before the onset of 
symptoms, allowing screening for cryptococcal infection and 
early treatment to prevent CM and CM-related mortality (2). 
However, few studies have been conducted in the United States 
to assess the prevalence of cryptococcal infection. To quantify 
the prevalence of undiagnosed cryptococcal infection in HIV-
infected persons in the United States during 1986–2012, stored 
sera from 1,872 participants in the Multicenter AIDS Cohort 
Study and the Women’s Interagency HIV Study with CD4 
T-cell counts <100 cells/µL were screened for CrAg, using 
the CrAg Lateral Flow Assay (LFA) (Immy, Inc.). This report 
describes the results of that analysis, which indicated the overall 
prevalence of CrAg positivity in this population to be 2.9% 
(95% confidence interval [CI] = 2.2%–3.7%). 
CrAg is detectable in serum a median of 3 weeks before 
the onset of symptoms of CM, making screening for serum 
CrAg and subsequent treatment of those with a positive test 
result a potential means of reducing CM-related mortality 
(2). In 2011, the World Health Organization declared early 
antiretroviral therapy (ART) initiation the most important 
and cost-effective preventive strategy to reduce the incidence 
and high mortality associated with CM. They further declared 
(as a conditional recommendation, given the low quality of 
evidence) that routine screening of and treatment for crypto-
coccal antigenemia might be considered before ART initiation 
for ART-naïve adults with a CD4 T-cell count <100 cells/µL 
in areas with a high prevalence (approximately 3%) of cryp-
tococcal antigenemia.*
There are few data from the United States on the prevalence 
of cryptococcal antigenemia. To estimate the prevalence, 
stored sera collected from 1986–2012 from the Multicenter 
AIDS Cohort Study and the Women’s Interagency HIV 
Study were screened for CrAg. To be eligible for the study, 
specimens needed to come from study participants who were 
HIV-infected, had a CD4 T-cell count <100 cells/µL, and 
had ≥0.5mL of stored serum available for testing. Sera from 
participants on and off ART were eligible for screening. Serum 
specimens randomly selected from those eligible were tested 
using the CrAg LFA. This is a Food and Drug Administration–
cleared CrAg detection test, which demonstrated a sensitivity 
of 100% for the detection of CrAg in archived sera from 704 
HIV-infected patients hospitalized for acute respiratory ill-
ness in Thailand (3). Chi-square and Student’s t-tests were 
performed to test differences between those with positive and 
negative CrAg test results. 
A total of 1,872 serum specimens from the Multicenter 
AIDS Cohort Study and the Women’s Interagency HIV Study 
were screened. The median age of the study population was 39 
years (range = 20–70 years). Of the 1,872 specimens, 55 (2.9% 
[CI = 2.2%–3.7%]) were positive for CrAg. No significant 
differences were observed in the proportion of CrAg-positive 
specimens by specimen collection year, age, sex, study loca-
tion, level of education, or race/ethnicity, except that persons 
of “other” ethnicity (i.e., not white, black, or Hispanic) had a 
prevalence of 6.4% (CI = 3.9%–10.3%) (Table). Persons with 
a CD4 count >50 cells/µL were less likely to be CrAg-positive 
compared with persons with a CD4 count ≤50 cells/µL (1.7% 
[CI = 1.1%–2.7%] and 4.3% [CI = 3.2%–5.9%], respectively).
Discussion
Results from this U.S. study indicated a 2.9% (CI = 2.2%–3.7%) 
prevalence of cryptococcal antigenemia in advanced AIDS 
patients. However, within certain subgroups, CrAg prevalences 
were higher. Existing prevalence data for CrAg antigenemia are 
mostly from resource-limited settings and range from as low as 
2% in northern Vietnam (4) to 21% in Benin City, Nigeria (5). 
South Africa, which began piloting CrAg screening in HIV-
infected patients with CD4 T-cell counts <100 cells/µL, and 
treatment of those with positive CrAg tests in 2012, reported 
a prevalence of 5% in the 12 months after the initiation of 
that program.†
In the United States, early access to ART has reduced the 
morbidity and mortality attributable to CM (6). However, the 
* Additional information available at http://www.who.int/hiv/pub/
cryptococcal_disease2011.
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incidence of CM among those with AIDS remains between 
two and seven cases per 1,000 persons, with a mortality rate 
as high as 12% (7). Late presentation to care among HIV-
infected persons remains a problem in the United States, with 
38% of persons newly diagnosed with HIV infection receiving 
an AIDS diagnosis concurrently or within the next year; these 
“late presenters” are more likely to be diagnosed and to die 
from preventable opportunistic infections, including CM.§
The devastating health effects of CM are compounded by 
the substantial clinical and financial burdens incurred when 
treating the disease. Treatment of CM requires toxic drugs, 
such as amphotericin B, repeated procedures, such as lumbar 
punctures, and close monitoring, all of which require hospital-
ization. In the United States, the mean hospital stay for persons 
diagnosed with CM is 14.7 days, costing, on average, $50,000 
(U.S.) for the entire hospital stay, and totaling $301.6 million 
spent per year treating CM (7). Those costs do not include 
the costs associated with complications, relapse, or outpatient 
care once a patient has been discharged. A proportion of 
CM cases are preventable, as was shown in an observational 
study conducted in Uganda: among ART-naïve, HIV-infected 
patients, with a CD4 T-cell count <100 cells/µL, the number 
needed to screen to prevent one case of CM was 11.3, and the 
number needed to screen to prevent one death was 15.9 (8). 
Therefore, screening would have tangible cost benefits because 
fewer cases of CM would mean less money spent on treating 
the disease. Several studies have examined the cost-effectiveness 
of CrAg screening. In a model using South African data, two 
screen-and-treat strategies, CrAg screening followed by high 
dose of fluconazole and CrAg screening followed by lumbar 
puncture, were compared to the standard of care, no screening 
(9). Both screen-and-treat strategies were more cost-effective 
than the standard of care. The least costly strategy was screen-
ing followed by high-dose fluconazole treatment, which was 
more cost-effective than the standard of care at prevalence 
levels ≥0.6%, lower than the estimated prevalences presented 
in this report (9).
The implementation of CrAg screening programs has begun 
in several countries, including South Africa, Rwanda, and 
Mozambique. However, in most of the world, including the 
United States, no recommendation for CrAg screening exists, 
despite the fact that a large number of HIV-infected persons 
present late to care every year, many of whom might benefit 
from CrAg screening. In 2013, the HIV Medicine Association 
of the Infectious Disease Society of America did not recom-
mend routine screening for CrAg, but stated that screening 
“may be considered in selected patients with CD4 cell counts 
<50 cells/µL” (10).
Inclusion of CrAg screening in a “late presenter” care pack-
age for HIV-infected persons in the United States has several 
advantages. Treatment of patients with isolated cryptococcal 
antigenemia has been shown to prevent the development 
of CM and CM-related death (7). Additionally, because 
those with cryptococcal antigenemia would likely undergo 
a lumbar puncture to be evaluated for CM, screening would 
likely improve the early diagnosis of CM. Early diagnosis of 
CM would translate into a reduction in CM-related deaths 
because patients who receive early antifungal treatment have 
TABLE. Selected characteristics of participants (N = 1,872) with tested 
specimens and cryptococcal antigen prevalence — Multicenter AIDS 
Cohort Study and Women’s Interagency HIV Study, United States, 
1986–2012
Characteristic No. (%)
Cryptococcal antigen 
prevalence
(%) (95% CI)
Total 1,872 (100) 2.9 (2.2–3.7)
Sex
 Male 989 (53.3) 2.6 (1.7–3.8)
 Female 866 (46.7) 3.3 (2.3–4.7)
Study location
 Baltimore, MD 241 (12.9) 3.0 (1.5–6.0)
 Bronx, NY 183 (9.9) 4.3 (2.2–8.4)
 Brooklyn, NY 162 (8.7) 1.9 (0.6–5.3)
 Chicago, IL 342 (18.4) 0.5 (0.1–2.8)
 District of Columbia 123 (6.6) 4.0 (1.7–9.1)
 Los Angeles, CA 514 (27.7) 3.3 (2.1–5.2)
 Pittsburgh, PA 187 (10.1) 4.2 (2.1–8.3)
 San Francisco, CA 103 (5.6) 3.9 (1.5–9.5)
Race/Ethnicity 
 White 849 (45.9) 2.5 (1.6–3.8)
 Black 651 (35.2) 2.5 (1.5–4.0)
 Hispanic 117 (6.3) 1.7 (0.5–6.7)
 Other 234 (12.6) 6.4 (3.9–10.3)
Education
 High school or less 790 (42.9) 3.8 (2.7–5.4)
 College 773 (42.1) 2.5 (1.6–3.8)
 Graduate school 275 (14.9) 1.5 (0.6–3.9)
Period of specimen collection
 1986–1990 485 (26.3) 2.1 (1.1–3.8)
 1991–1995 620 (33.7) 3.6 (2.4–5.3)
 1996–2000 255 (13.9) 1.6 (0.6–4.0)
 2001–2005 288 (15.6) 3.5 (1.9–6.3)
 2006–2012 193 (10.5) 3.6 (1.8–7.3)
Age group (yrs)
  20–30 188 (10.0) 2.1 (0.8–5.4)
  31–40 775 (41.4) 3.1 (2.1–4.6)
  41–50 556 (29.7) 2.5 (1.5–4.2)
  51–60 142 (7.6) 4.2 (2.0–8.9)
  ≥61 18 (9.6) 5.6 (1.0–25.8)
CD4 count
 >50 cells/μL 992 (53.0) 1.7 (1.1–2.7)
 ≤50 cells/μL 881 (47.1) 4.3 (3.2–5.9)
Receiving ART at time of specimen collection
 Yes 1,047 (55.9) 1.4 (1.0–2.1)
 No 743 (39.7) 1.4 (1.0–2.1)
Abbreviations: CI = confidence interval; ART = antiretroviral therapy.
§ Additional information available at http://www.cdc.gov/mmwr/preview/
mmwrhtml/mm5824a2.htm.
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been shown to have better outcomes than those who receive 
delayed treatment (8).
This study has several limitations. First, the study spanned 
more than two decades and includes many participants who 
were diagnosed before the advent of highly active ART. 
Predictors of cryptococcal infection might be different among 
groups before and after the introduction of highly active ART. 
However, when CrAg results were compared by various peri-
ods and current ART use, no differences were found. Second, 
no lumbar puncture results were available to help determine 
what proportion of patients with a positive serum CrAg result 
had prior or incident CM. Finally, this study was conducted 
using participants from the Multicenter AIDS Cohort Study 
and Women’s Interagency HIV Study, both of which include 
participants that might not be representative of the U.S. HIV/
AIDS population.
These findings provide national CrAg seroprevalence data 
for HIV-infected persons with CD4 T-cell count <100 cells/µL 
in the United States. The findings show the prevalence to be 
above the published cost-effectiveness thresholds in resource-
limited countries and on par with many other countries that 
are currently pursuing programs of routine CrAg screening 
and treatment. Based on these data, updated strategies for the 
prevention of CM among AIDS patients in the United States 
should be considered.
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What is already known on this topic?
Cryptococcal meningitis is the leading opportunistic infection 
worldwide among persons infected with human immunodefi-
ciency virus (HIV). No recent study of the prevalence of 
cryptococcal antigenemia among HIV-infected persons has 
been conducted in the United States.
What is added by this report?
Serum specimens from HIV-infected persons with low CD4 T-cell 
counts enrolled in studies in the United States during 1986–
2012 were screened for cryptococcal antigen using a new lateral 
flow assay. The prevalence of cryptococcal antigenemia was 
2.9% (95% confidence interval = 2.2%–3.7%).
What are the implications for public health practice?
The prevalence of cryptococcal infection among patients with 
advanced acquired immunodeficiency syndrome (AIDS) in the 
United States is high enough that screening for cryptococcal 
antigenemia might save lives and be cost-effective.
